CancerDrs

Lymphoma clinical trials in Montana

11 actively recruiting lymphoma trials at 9 sites across Montana.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Montana:
  • Community Hospital of Anaconda — Anaconda, Montana
  • Billings Clinic Cancer Center — Billings, Montana
  • Saint Vincent Healthcare — Billings, Montana
  • Saint Vincent Frontier Cancer Center — Billings, Montana
  • Bozeman Health Deaconess Hospital — Bozeman, Montana
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal a…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Montana:
  • Community Hospital of Anaconda — Anaconda, Montana
  • Billings Clinic Cancer Center — Billings, Montana
  • Saint Vincent Healthcare — Billings, Montana
  • Saint Vincent Frontier Cancer Center — Billings, Montana
  • Bozeman Health Deaconess Hospital — Bozeman, Montana
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in Montana:
  • Community Hospital of Anaconda — Anaconda, Montana
  • Billings Clinic Cancer Center — Billings, Montana
  • Bozeman Health Deaconess Hospital — Bozeman, Montana
  • Benefis Sletten Cancer Institute — Great Falls, Montana
  • Logan Health Medical Center — Kalispell, Montana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This st…

Sponsor: Genmab
NCT ID: NCT06191744
Sites in Montana:
  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 260006 — Billings, Montana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06717347
Sites in Montana:
  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0178) — Billings, Montana
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutin…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04840602
Sites in Montana:
  • Saint Vincent Frontier Cancer Center — Billings, Montana
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06890884
Sites in Montana:
  • Bozeman Health Deaconess Hospital ( Site 0183) — Bozeman, Montana
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Montana:
  • Community Hospital of Anaconda — Anaconda, Montana
  • Billings Clinic Cancer Center — Billings, Montana
  • Bozeman Health Deaconess Hospital — Bozeman, Montana
  • Benefis Sletten Cancer Institute — Great Falls, Montana
  • Great Falls Clinic — Great Falls, Montana
View on ClinicalTrials.gov →
Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Montana:
  • Community Hospital of Anaconda — Anaconda, Montana
  • Billings Clinic Cancer Center — Billings, Montana
  • Montana Cancer Consortium NCORP — Billings, Montana
  • Bozeman Health Deaconess Hospital — Bozeman, Montana
  • Benefis Sletten Cancer Institute — Great Falls, Montana
View on ClinicalTrials.gov →
Recruiting Network

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer …

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06002828
Sites in Montana:
  • Saint Patrick Hospital - Community Hospital — Missoula, Montana
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Montana:
  • Massive Bio SYNERGY-AI site — Billings, Montana
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25